The efficacy, safety and positioning of inhaled corticosteroids (ICS) in the treatment of
patients with chronic obstructive pulmonary disease (COPD) is much debated, since it can …

BACKGROUND: COPD is a major cause of morbidity and mortality in the United States as
well as throughout the rest of the world. An exacerbation of COPD (periodic escalations of …

Background Most guidelines recommend either a long-acting beta-agonist (LABA) plus an
inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice …

Background Blood eosinophil counts might predict response to inhaled corticosteroids (ICS)
in patients with chronic obstructive pulmonary disease (COPD) and a history of …

Rationale: There are no studies on withdrawal of inhaled corticosteroids in patients on long-
term triple therapy in the absence of frequent exacerbations. Objectives: To evaluate the …

Background Despite the availability of national and international guidelines, evidence
suggests that chronic obstructive pulmonary disease (COPD) treatment is not always …

Chronic obstructive pulmonary disease (COPD) is a common, complex, and heterogeneous
disorder that is responsible for substantial and growing morbidity, mortality, and health-care …

Rationale: Post hoc analyses suggest that blood eosinophils have potential as a predictive
biomarker of inhaled corticosteroid efficacy in the management of chronic obstructive …

Intrinsically stretchable conductive self-healable organogels containing poly (lipoic acid),
Al3+ ion, tannic acid, and reduced graphene oxide are produced in this report. These …

Background Real-world prescription pathways leading to triple therapy (TT)(inhaled
corticosteroid [ICS] plus long-acting β2-agonist bronchodilator [LABA] plus long-acting …